Skip to main content
Signal8

Mayne Pharma Group Limited (MAYNF)

Mayne Pharma Group Limited is an Australian-headquartered specialty pharmaceutical enterprise, engaged in the development, production, and marketing of both patented (branded) and generic drug formulations. Its commercial reach spans Australia, New Zealand, North America (covering the United States and Canada), Europe, and Asia. The company's operations are divided into four main segments: Metrics Contract Services, International, Branded Products, and Portfolio Products. Beyond its own product lines, Mayne Pharma offers sophisticated oral drug delivery technologies and comprehensive contract services—including pharmaceutical development, manufacturing, and analytical testing—to other businesses. Its strategic focus areas for specialty product distribution include dermatology, women's health, and infectious disease treatments. Originally established in 2005, the company operated under the name Halcygen Pharmaceuticals Limited before rebranding to Mayne Pharma Group Limited in November 2010. Its principal office is located in Salisbury South, Australia.

Sector: Medical - Pharmaceuticals

Industry: Medical - Pharmaceuticals

Mayne Pharma Group Limited logo

Mayne Pharma Group Limited

OTC:MAYNFHealthcare
-4.15%$2.19
CLOSED
Mkt Cap$179.75M
EV-
Float75.6M
O/S81.89M
VOL12K sh
$ Vol$26K
RVOL1.68×
Inst Own-
SI0.1%
Net Cash/Sh-
EarningsFeb 24 · in 3mo
Dilution
Mayne Pharma Group Limited logoOTC:MAYNFClosed$2.19-4.15%
FormDescription
    Mayne Pharma Group Limited (MAYNF) SEC Filings | Signal8